Inflammation and post-traumatic stress disorder

Psychiatry and Clinical Neurosciences

Volumn 73, Issue 4, 2019, Pages 143-153

  Hori, Hiroaki ^a   Kim, Yoshiharu ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

cytokine; inflammation; neuroinflammation; post traumatic stress disorder; treatment

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CANDESARTAN; CANNABIS; CAPTOPRIL; CELECOXIB; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; IBUPROFEN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; NABILONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYTOCIN; PAROXETINE; PREDNISOLONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TELMISARTAN; TOCILIZUMAB; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; CHRONIC STRESS; DEPRESSION; DISEASE ASSOCIATION; EMOTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; METABOLIC DISORDER; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; REVIEW; RISK FACTOR; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; STRESS DISORDERS, POST-TRAUMATIC;

EID: 85061995341     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12820     Document Type: Review

References (162)

1. Koenen KC, Ratanatharathorn A, Ng L et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol. Med. 2017; 47: 2260–2274.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Publishing, Arlington, VA, 2013.
3. Brewin CR. A cognitive neuroscience account of posttraumatic stress disorder and its treatment. Behav. Res. Ther. 2001; 39: 373–393.
4. McNally RJ. Cognitive abnormalities in post-traumatic stress disorder. Trends Cogn. Sci. 2006; 10: 271–277.
5. Ehlers A, Clark DM. A cognitive model of posttraumatic stress disorder. Behav. Res. Ther. 2000; 38: 319–345.
6. Michopoulos V, Vester A, Neigh G. Posttraumatic stress disorder: A metabolic disorder in disguise? Exp. Neurol. 2016; 284: 220–229.
7. Mellon SH, Gautam A, Hammamieh R, Jett M, Wolkowitz OM. Metabolism, metabolomics, and inflammation in posttraumatic stress disorder. Biol. Psychiatry 2018; 83: 866–875.
8. Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. Am. Heart J. 2013; 166: 806–814.
9. O'Donovan A, Cohen BE, Seal KH et al. Elevated risk for autoimmune disorders in Iraq and Afghanistan veterans with posttraumatic stress disorder. Biol. Psychiatry 2015; 77: 365–374.
10. Song H, Fang F, Tomasson G et al. Association of stress-related disorders with subsequent autoimmune disease. JAMA 2018; 319: 2388–2400.
11. Renault PF, Hoofnagle JH, Park Y et al. Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med. 1987; 147: 1577–1580.
12. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010; 67: 446–457.
13. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom. Med. 2009; 71: 171–186.
14. Sasayama D, Hattori K, Wakabayashi C et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J. Psychiatr. Res. 2013; 47: 401–406.
15. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol. Psychiatry 2011; 70: 663–671.
16. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol. Psychiatry 2013; 74: 15–25.
17. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: Immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol. Psychiatry 2012; 17: 389–401.
18. Passos IC, Vasconcelos-Moreno MP, Costa LG et al. Inflammatory markers in post-traumatic stress disorder: A systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2015; 2: 1002–1012.
19. Stein MB, Chen CY, Ursano RJ et al. Genome-wide association studies of posttraumatic stress disorder in 2 cohorts of US Army soldiers. JAMA Psychiatry 2016; 73: 695–704.
20. Uddin M, Aiello AE, Wildman DE et al. Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 9470–9475.
21. Breen MS, Tylee DS, Maihofer AX et al. PTSD blood transcriptome mega-analysis: Shared inflammatory pathways across biological sex and modes of trauma. Neuropsychopharmacology 2018; 43: 469–481.
22. Neylan TC, Sun B, Rempel H et al. Suppressed monocyte gene expression profile in men versus women with PTSD. Brain Behav. Immun. 2011; 25: 524–531.
23. Imai R, Hori H, Itoh M et al. Inflammatory markers and their possible effects on cognitive function in women with posttraumatic stress disorder. J. Psychiatr. Res. 2018; 102: 192–200.
24. Teche SP, Rovaris DL, Aguiar BW et al. Resilience to traumatic events related to urban violence and increased IL10 serum levels. Psychiatry Res. 2017; 250: 136–140.
25. Lindqvist D, Dhabhar FS, Mellon SH et al. Increased pro-inflammatory milieu in combat related PTSD: A new cohort replication study. Brain Behav. Immun. 2017; 59: 260–264.
26. de Oliveira JF, Wiener CD, Jansen K et al. Serum levels of interleukins IL-6 and IL-10 in individuals with posttraumatic stress disorder in a population-based sample. Psychiatry Res. 2018; 260: 111–115.
27. Bruenig D, Mehta D, Morris CP et al. Genetic and serum biomarker evidence for a relationship between TNFα and PTSD in Vietnam War combat veterans. Compr. Psychiatry 2017; 74: 125–133.
28. O'Donovan A, Ahmadian AJ, Neylan TC, Pacult MA, Edmondson D, Cohen BE. Current posttraumatic stress disorder and exaggerated threat sensitivity associated with elevated inflammation in the Mind Your Heart Study. Brain Behav. Immun. 2017; 60: 198–205.
29. Miller K, Driscoll D, Smith LM, Ramaswamy S. The role of inflammation in late-life post-traumatic stress disorder. Mil. Med. 2017; 182: e1815–e1818.
30. Miller MW, Maniates H, Wolf EJ et al. CRP polymorphisms and DNA methylation of the AIM2 gene influence associations between trauma exposure, PTSD, and C-reactive protein. Brain Behav. Immun. 2018; 67: 194–202.
31. Sondergaard HP, Hansson LO, Theorell T. The inflammatory markers C-reactive protein and serum amyloid A in refugees with and without posttraumatic stress disorder. Clin. Chim. Acta 2004; 342: 93–98.
32. Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, Simon NM. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress. Anxiety 2009; 26: 447–455.
33. Guo M, Liu T, Guo JC, Jiang XL, Chen F, Gao YS. Study on serum cytokine levels in posttraumatic stress disorder patients. Asian Pac. J. Trop. Med. 2012; 5: 323–325.
34. Smith AK, Conneely KN, Kilaru V et al. Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011; 156B: 700–708.
35. Rohleder N, Joksimovic L, Wolf JM, Kirschbaum C. Hypocortisolism and increased glucocorticoid sensitivity of pro-inflammatory cytokine production in Bosnian war refugees with posttraumatic stress disorder. Biol. Psychiatry 2004; 55: 745–751.
36. Gill J, Vythilingam M, Page GG. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J. Trauma. Stress 2008; 21: 530–539.
37. Tursich M, Neufeld RW, Frewen PA et al. Association of trauma exposure with proinflammatory activity: A transdiagnostic meta-analysis. Transl. Psychiatry 2014; 4: e413.
38. McCanlies EC, Araia SK, Joseph PN et al. C-reactive protein, interleukin-6, and posttraumatic stress disorder symptomology in urban police officers. Cytokine 2011; 55: 74–78.
39. Plantinga L, Bremner JD, Miller AH et al. Association between posttraumatic stress disorder and inflammation: A twin study. Brain Behav. Immun. 2013; 30: 125–132.
40. Baker DG, Ekhator NN, Kasckow JW et al. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation 2001; 9: 209–217.
41. Bonne O, Gill JM, Luckenbaugh DA et al. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry 2011; 72: 1124–1128.
42. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 1995; 52: 1048–1060.
43. Perkonigg A, Kessler RC, Storz S, Wittchen HU. Traumatic events and post-traumatic stress disorder in the community: Prevalence, risk factors and comorbidity. Acta Psychiatr. Scand. 2000; 101: 46–59.
44. McLaughlin KA, Koenen KC, Bromet EJ et al. Childhood adversities and post-traumatic stress disorder: Evidence for stress sensitisation in the World Mental Health Surveys. Br. J. Psychiatry 2017; 211: 280–288.
45. Scott KM, Smith DR, Ellis PM. Prospectively ascertained child maltreatment and its association with DSM-IV mental disorders in young adults. Arch. Gen. Psychiatry 2010; 67: 712–719.
46. Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016; 16: 22–34.
47. Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: A meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. Mol. Psychiatry 2016; 21: 642–649.
48. Coelho R, Viola TW, Walss-Bass C, Brietzke E, Grassi-Oliveira R. Childhood maltreatment and inflammatory markers: A systematic review. Acta Psychiatr. Scand. 2014; 129: 180–192.
49. von Känel R, Hepp U, Kraemer B et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J. Psychiatr. Res. 2007; 41: 744–752.
50. Eraly SA, Nievergelt CM, Maihofer AX et al. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry 2014; 71: 423–431.
51. Breen MS, Maihofer AX, Glatt SJ et al. Gene networks specific for innate immunity define post-traumatic stress disorder. Mol. Psychiatry 2015; 20: 1538–1545.
52. Michopoulos V, Rothbaum AO, Jovanovic T et al. Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma. Am. J. Psychiatry 2015; 172: 353–362.
53. Nusslock R, Miller GE. Early-life adversity and physical and emotional health across the lifespan: A neuroimmune network hypothesis. Biol. Psychiatry 2016; 80: 23–32.
54. Sumner JA, Chen Q, Roberts AL et al. Posttraumatic stress disorder onset and inflammatory and endothelial function biomarkers in women. Brain Behav. Immun. 2018; 69: 203–209.
55. Kawamura N, Kim Y, Asukai N. Suppression of cellular immunity in men with a past history of posttraumatic stress disorder. Am. J. Psychiatry 2001; 158: 484–486.
56. Gill JM, Saligan L, Lee H, Rotolo S, Szanton S. Women in recovery from PTSD have similar inflammation and quality of life as non-traumatized controls. J. Psychosom. Res. 2013; 74: 301–306.
57. Gola H, Engler H, Sommershof A et al. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry 2013; 13: 40.
58. Fleshner M, Frank M, Maier SF. Danger signals and inflammasomes: Stress-evoked sterile inflammation in mood disorders. Neuropsychopharmacology 2017; 42: 36–45.
59. Franklin TC, Xu C, Duman RS. Depression and sterile inflammation: Essential role of danger associated molecular patterns. Brain Behav. Immun. 2018; 72: 2–13.
60. Powell ND, Bailey MT, Mays JW et al. Repeated social defeat activates dendritic cells and enhances toll-like receptor dependent cytokine secretion. Brain Behav. Immun. 2009; 23: 225–231.
61. Wei L, Simen A, Mane S, Kaffman A. Early life stress inhibits expression of a novel innate immune pathway in the developing hippocampus. Neuropsychopharmacology 2012; 37: 567–580.
62. Daskalakis NP, Cohen H, Nievergelt CM et al. New translational perspectives for blood-based biomarkers of PTSD: From glucocorticoid to immune mediators of stress susceptibility. Exp. Neurol. 2016; 284: 133–140.
63. Hendrickson RC, Raskind MA. Noradrenergic dysregulation in the pathophysiology of PTSD. Exp. Neurol. 2016; 284: 181–195.
64. ter Heegde F, De Rijk RH, Vinkers CH. The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology 2015; 52: 92–110.
65. Galic MA, Riazi K, Pittman QJ. Cytokines and brain excitability. Front. Neuroendocrinol. 2012; 33: 116–125.
66. Bierhaus A, Wolf J, Andrassy M et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 1920–1925.
67. Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenko L, Flood PM. Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell. Signal. 2007; 19: 251–260.
68. Morris MC, Compas BE, Garber J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: A systematic review and meta-analysis. Clin. Psychol. Rev. 2012; 32: 301–315.
69. Bremner JD, Licinio J, Darnell A et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am. J. Psychiatry 1997; 154: 624–629.
70. Baker DG, West SA, Nicholson WE et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am. J. Psychiatry 1999; 156: 585–588.
71. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: Molecular mechanisms for gene repression. Endocr. Rev. 2003; 24: 488–522.
72. Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol. Cell. Endocrinol. 2002; 189: 1–9.
73. Gustavson SM, Sandoval DA, Ertl AC, Bao S, Raj SR, Davis SN. Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am. J. Physiol. Endocrinol. Metab. 2008; 294: E506–E512.
74. Joëls M, Fernandez G, Roozendaal B. Stress and emotional memory: A matter of timing. Trends Cogn. Sci. 2011; 15: 280–288.
75. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477–501.
76. Yehuda R, McFarlane AC, Shalev AY. Predicting the development of posttraumatic stress disorder from the acute response to a traumatic event. Biol. Psychiatry 1998; 44: 1305–1313.
77. Yehuda R, Bierer LM, Schmeidler J, Aferiat DH, Breslau I, Dolan S. Low cortisol and risk for PTSD in adult offspring of holocaust survivors. Am. J. Psychiatry 2000; 157: 1252–1259.
78. Binder EB, Bradley RG, Liu W et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008; 299: 1291–1305.
79. Mehta D, Gonik M, Klengel T et al. Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: Evidence from endocrine and gene expression studies. Arch. Gen. Psychiatry 2011; 68: 901–910.
80. Lee YS, Wollam J, Olefsky JM. An integrated view of immunometabolism. Cell 2018; 172: 22–40.
81. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017; 542: 177–185.
82. van den Berk-Clark C, Secrest S, Walls J et al. Association between posttraumatic stress disorder and lack of exercise, poor diet, obesity, and co-occuring smoking: A systematic review and meta-analysis. Health Psychol. 2018; 37: 407–416.
83. Hall KS, Hoerster KD, Yancy WS Jr. Post-traumatic stress disorder, physical activity, and eating behaviors. Epidemiol. Rev. 2015; 37: 103–115.
84. Hirth JM, Rahman M, Berenson AB. The association of posttraumatic stress disorder with fast food and soda consumption and unhealthy weight loss behaviors among young women. J. Womens Health (Larchmt.) 2011; 20: 1141–1149.
85. O'Connor MF, Bower JE, Cho HJ et al. To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers. Brain Behav. Immun. 2009; 23: 887–897.
86. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 2008; 9: 46–56.
87. Levin SG, Godukhin OV. Modulating effect of cytokines on mechanisms of synaptic plasticity in the brain. Biochemistry 2017; 82: 264–274.
88. Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 2018; 19: 622–635.
89. Réus GZ, Fries GR, Stertz L et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015; 300: 141–154.
90. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: The 'collusion' hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. J. Neuroinflammation 2012; 9: 275.
91. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 2011; 11: 775–787.
92. Myint AM, Schwarz MJ, Müller N. The role of the kynurenine metabolism in major depression. J. Neural Transm. 2012; 119: 245–251.
93. Dostal CR, Gamsby NS, Lawson MA, McCusker RH. Glia- and tissue-specific changes in the Kynurenine Pathway after treatment of mice with lipopolysaccharide and dexamethasone. Brain Behav. Immun. 2018; 69: 321–335.
94. Liberzon I, Taylor SF, Amdur R et al. Brain activation in PTSD in response to trauma-related stimuli. Biol. Psychiatry 1999; 45: 817–826.
95. Fonzo GA, Simmons AN, Thorp SR, Norman SB, Paulus MP, Stein MB. Exaggerated and disconnected insular-amygdalar blood oxygenation level-dependent response to threat-related emotional faces in women with intimate-partner violence posttraumatic stress disorder. Biol. Psychiatry 2010; 68: 433–441.
96. Quiñones MM, Maldonado L, Velazquez B, Porter JT. Candesartan ameliorates impaired fear extinction induced by innate immune activation. Brain Behav. Immun. 2016; 52: 169–177.
97. Yu Z, Fukushima H, Ono C et al. Microglial production of TNF-alpha is a key element of sustained fear memory. Brain Behav. Immun. 2017; 59: 313–321.
98. Young MB, Howell LL, Hopkins L et al. A peripheral immune response to remembering trauma contributes to the maintenance of fear memory in mice. Psychoneuroendocrinology 2018; 94: 143–151.
99. Inagaki TK, Muscatell KA, Irwin MR, Cole SW, Eisenberger NI. Inflammation selectively enhances amygdala activity to socially threatening images. Neuroimage 2012; 59: 3222–3226.
100. Swartz JR, Prather AA, Hariri AR. Threat-related amygdala activity is associated with peripheral CRP concentrations in men but not women. Psychoneuroendocrinology 2017; 78: 93–96.
101. de Quervain D, Schwabe L, Roozendaal B. Stress, glucocorticoids and memory: Implications for treating fear-related disorders. Nat. Rev. Neurosci. 2017; 18: 7–19.
102. Henckens MJ, van Wingen GA, Joëls M, Fernández G. Time-dependent effects of corticosteroids on human amygdala processing. J. Neurosci. 2010; 30: 12725–12732.
103. Narita-Ohtaki R, Hori H, Itoh M et al. Cognitive function in Japanese women with posttraumatic stress disorder: Association with exercise habits. J. Affect. Disord. 2018; 236: 306–312.
104. Scott JC, Matt GE, Wrocklage KM et al. A quantitative meta-analysis of neurocognitive functioning in posttraumatic stress disorder. Psychol. Bull. 2015; 141: 105–140.
105. Flatt JD, Gilsanz P, Quesenberry CP Jr, Albers KB, Whitmer RA. Post-traumatic stress disorder and risk of dementia among members of a health care delivery system. Alzheimers Dement. 2017; 14: 28–34.
106. Yaffe K, Vittinghoff E, Lindquist K et al. Posttraumatic stress disorder and risk of dementia among US veterans. Arch. Gen. Psychiatry 2010; 67: 608–613.
107. Aupperle RL, Allard CB, Grimes EM et al. Dorsolateral prefrontal cortex activation during emotional anticipation and neuropsychological performance in posttraumatic stress disorder. Arch. Gen. Psychiatry 2012; 69: 360–371.
108. Bremner JD, Elzinga B, Schmahl C, Vermetten E. Structural and functional plasticity of the human brain in posttraumatic stress disorder. Prog. Brain Res. 2008; 167: 171–186.
109. Kuhn S, Gallinat J. Gray matter correlates of posttraumatic stress disorder: A quantitative meta-analysis. Biol. Psychiatry 2013; 73: 70–74.
110. Li L, Wu M, Liao Y et al. Grey matter reduction associated with posttraumatic stress disorder and traumatic stress. Neurosci. Biobehav. Rev. 2014; 43: 163–172.
111. Gruol DL. IL-6 regulation of synaptic function in the CNS. Neuropharmacology 2015; 96: 42–54.
112. Spooren A, Kolmus K, Laureys G et al. Interleukin-6, a mental cytokine. Brain Res. Rev. 2011; 67: 157–183.
113. Trapero I, Cauli O. Interleukin 6 and cognitive dysfunction. Metab. Brain Dis. 2014; 29: 593–608.
114. Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E. Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol. Lett. 2011; 32: 540–544.
115. Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr. Res. 2018; 192: 16–29.
116. Levandowski ML, Hess AR, Grassi-Oliveira R, de Almeida RM. Plasma interleukin-6 and executive function in crack cocaine-dependent women. Neurosci. Lett. 2016; 628: 85–90.
117. Wada-Isoe K, Wakutani Y, Urakami K, Nakashima K. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Neurol. Scand. 2004; 110: 124–127.
118. Yang J, Fan C, Pan L et al. C-reactive protein plays a marginal role in cognitive decline: A systematic review and meta-analysis. Int. J. Geriatr. Psychiatry 2015; 30: 156–165.
119. Hoskins M, Pearce J, Bethell A et al. Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Br. J. Psychiatry 2015; 206: 93–100.
120. Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments. Depress. Anxiety 2016; 33: 792–806.
121. Aerni A, Traber R, Hock C et al. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am. J. Psychiatry 2004; 161: 1488–1490.
122. Surís A, North C, Adinoff B, Powell CM, Greene R. Effects of exogenous glucocorticoid on combat-related PTSD symptoms. Ann. Clin. Psychiatry 2010; 22: 274–279.
123. Yehuda R, Bierer LM, Pratchett LC et al. Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: Randomized trial showing improved treatment retention and outcome. Psychoneuroendocrinology 2015; 51: 589–597.
124. Khoury NM, Marvar PJ, Gillespie CF et al. The renin-angiotensin pathway in posttraumatic stress disorder: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J. Clin. Psychiatry 2012; 73: 849–855.
125. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci. Ther. 2009; 15: 84–88.
126. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation. J. Clin. Psychopharmacol. 2014; 34: 559–564.
127. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 2015; 51: 585–588.
128. Köhler O, Benros ME, Nordentoft M et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71: 1381–1391.
129. Lee B, Sur B, Yeom M, Shim I, Lee H, Hahm DH. Effects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder. Korean J. Physiol. Pharmacol. 2016; 20: 357–366.
130. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry 2018; 23: 335–343.
131. Schelling G, Roozendaal B, Krauseneck T, Schmoelz M, DE Quervain D, Briegel J. Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery. Ann. N. Y. Acad. Sci. 2006; 1071: 46–53.
132. Zohar J, Yahalom H, Kozlovsky N et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: Interplay between clinical and animal studies. Eur. Neuropsychopharmacol. 2011; 21: 796–809.
133. Kortekaas KE, Meijer CA, Hinnen JW et al. ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm. PLoS One. 2014; 9: e111952.
134. Clancy P, Koblar SA, Golledge J. Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. Atherosclerosis 2014; 236: 108–115.
135. Hill MN, Campolongo P, Yehuda R, Patel S. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology 2018; 43: 80–102.
136. Steenkamp MM, Blessing EM, Galatzer-Levy IR, Hollahan LC, Anderson WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depress. Anxiety 2017; 34: 207–216.
137. Feldman R. Oxytocin and social affiliation in humans. Horm. Behav. 2012; 61: 380–391.
138. Cochran DM, Fallon D, Hill M, Frazier JA. The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings. Harv. Rev. Psychiatry 2013; 21: 219–247.
139. Donadon MF, Martin-Santos R, Osório FL. The associations between oxytocin and trauma in humans: A systematic review. Front. Pharmacol. 2018; 9: 154.
140. Garrido-Urbani S, Deblon N, Poher AL et al. Inhibitory role of oxytocin on TNFα expression assessed in vitro and in vivo. Diabetes Metab. 2018; 44: 292–295.
141. Clodi M, Vila G, Geyeregger R et al. Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am. J. Physiol. Endocrinol. Metab. 2008; 295: E686–E691.
142. Walker FR. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology 2013; 67: 304–317.
143. Gałecki P, Mossakowska-Wójcik J, Talarowska M. The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2018; 80: 291–294.
144. Tucker P, Ruwe WD, Masters B et al. Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol. Psychiatry 2004; 56: 121–128.
145. Nishi D, Koido Y, Nakaya N et al. Fish oil for attenuating posttraumatic stress symptoms among rescue workers after the Great East Japan Earthquake: A randomized controlled trial. Psychother. Psychosom. 2012; 81: 315–317.
146. Rosenbaum S, Vancampfort D, Steel Z, Newby J, Ward PB, Stubbs B. Physical activity in the treatment of post-traumatic stress disorder: A systematic review and meta-analysis. Psychiatry Res. 2015; 230: 130–136.
147. Uemura M, Ohira T, Yasumura S et al. Association between psychological distress and dietary intake among evacuees after the Great East Japan Earthquake in a cross-sectional study: The Fukushima Health Management Survey. BMJ Open 2016; 6: e011534.
148. Nicklas BJ, Brinkley TE. Exercise training as a treatment for chronic inflammation in the elderly. Exerc. Sport Sci. Rev. 2009; 37: 165–170.
149. Bower JE, Irwin MR. Mind-body therapies and control of inflammatory biology: A descriptive review. Brain Behav. Immun. 2016; 51: 1–11.
150. Calder PC, Ahluwalia N, Brouns F et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 2011; 106: S5–S78.
151. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat. Neurosci. 2017; 20: 145–155.
152. Erny D, Hrabě de Angelis AL, Jaitin D et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 2015; 18: 965–977.
153. Hemmings SMJ, Malan-Müller S, van den Heuvel LL et al. The microbiome in posttraumatic stress disorder and trauma-exposed controls: An exploratory study. Psychosom. Med. 2017; 79: 936–946.
154. Holmes SE, Hinz R, Conen S et al. Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: A positron emission tomography study. Biol. Psychiatry 2018; 83: 61–69.
155. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J. Trauma. Stress 2013; 26: 537–547.
156. Blanco C, Hoertel N, Wall MM et al. Toward understanding sex differences in the prevalence of posttraumatic stress disorder: Results from the National Epidemiologic Survey on alcohol and related conditions. J. Clin. Psychiatry 2018; 79: 16m11364.
157. Stein MB, Jang KL, Taylor S, Vernon PA, Livesley WJ. Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: A twin study. Am. J. Psychiatry 2002; 159: 1675–1681.
158. Sartor CE, McCutcheon VV, Pommer NE et al. Common genetic and environmental contributions to post-traumatic stress disorder and alcohol dependence in young women. Psychol. Med. 2011; 41: 1497–1505.
159. Ferree NK, Kamat R, Cahill L. Influences of menstrual cycle position and sex hormone levels on spontaneous intrusive recollections following emotional stimuli. Conscious. Cogn. 2011; 20: 1154–1162.
160. Wegerer M, Kerschbaum H, Blechert J, Wilhelm FH. Low levels of estradiol are associated with elevated conditioned responding during fear extinction and with intrusive memories in daily life. Neurobiol. Learn. Mem. 2014; 116: 145–154.
161. Olff M, Langeland W, Draijer N, Gersons BP. Gender differences in posttraumatic stress disorder. Psychol. Bull. 2007; 133: 183–204.
162. Insel T, Cuthbert B, Garvey M et al. Research Domain Criteria (RDoC): Toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010; 167: 748–751.